Healthcare Global Enterprises Ltd Q1 FY2027 Concall Summary

Key Takeaways

• 13% revenue growth, margin-accretive headwinds: Revenue grew 13% YoY, held back ~1.5% by deliberate discontinuation of high-value, low-margin chemo drugs and ~1.5% by CGHS price capping; both were margin-positive, helping adjusted EBITDA margin expand to 19.4% from 18.2% in Q1 FY26.
• North Bangalore peak loss reached: The new hospital opened in May, incurred most of its start-up costs, and management believes Q1 marked the peak EBITDA loss; monthly breakeven is expected this year, making the ramp-down of losses a near-term margin lever.
• Payor mix is the core margin engine: Non-institutional revenue grew 17% YoY and now contributes 69% of the mix, up 200 bps; management calls this the biggest lever for margin expansion, with a target of 24–25% in the next few years.
• Bed expansion plan is front-loaded and brownfield-heavy: 65 beds in FY27, then 520 across FY28–FY29, nearly 60% brownfield; three greenfield projects are in the pipeline, with Whitefield likely operational by end-FY28 and the other in the subsequent year.
• What to watch next quarter: Whether North Bangalore losses decline as promised, the pace of payor mix improvement, and the ESOP charge quantum once grants are finalized.

Revenue Growth & Headwinds

• Volume-led, broad-based: 11% patient volume growth drove the 13% revenue increase; 16 of 25 centers (ex-North Bangalore) posted their highest-ever quarterly revenues, spanning all hospital size buckets.
• Two deliberate top-line drags: Discontinued chemo drugs shaved ~1.5% from growth (would have been ~15% otherwise) and CGHS price capping another ~1.5%; both improved margins and the drug impact is expected to persist at similar levels for the next few quarters, potentially easing as higher-margin cash business replaces it.
• ARPP grew 2%: Favourable payor mix drove the increase, partly offset by case-mix changes including a lower contribution from high-value, low-margin therapies; management expects future ARPP growth in line with inflation.
• West cluster moderated deliberately: 9% YoY growth with institutional business declining >4%, consistent with the strategy of replacing low-margin scheme business (particularly immunotherapies in Gujarat) with higher-value cash and non-institutional patients; Maharashtra grew >14%.
• East cluster standout: 22% YoY growth on robust volumes, though ARPP moderated temporarily.

Mattoo: "The impact in Q1 has been about 1.5% on our top line. And that is why I think if we were to plow that back, the top line would have been around 15%. But having said that, we have discontinued those drugs because while they were high value, they were low margin."

Margin Trajectory & Levers

• Adjusted EBITDA margin expanded 120 bps YoY to 19.4%: EBITDA grew 20% YoY to ₹133.9 crore, outpacing revenue growth through operating leverage from maturing centers, payor mix improvement, and cost optimization.
• Four expansion levers, sequenced: Payor mix improvement is the largest and already visible; clinical and technology investments (MR-LINAC, TomoTherapy, surgical robots, CAR-T, BMT programs) improve case mix; operating leverage from existing centers; and North Bangalore maturation as losses decline.
• Marketing spend stepped up: Rose 20% YoY to 2.9% of sales, driven by the North Bangalore launch and intensified branding efforts; management expects long-term run-rate of 2.5–2.6%.
• Interest cost declined: ~₹170 crore of rights issue proceeds were used to repay debt, reducing interest costs during the quarter.
• Two-year and five-year margin targets: 21–22% EBITDA margin in the next two years, scaling to 24–25% in four to five years; management expressed confidence given Q1 performance and the levers in place.

Mattoo: "The big piece will come from improvement in our payor mix. That is the biggest lever, and we have already seen that happen consistently over the last couple of quarters."

North Bangalore Ramp-Up

• Opened May 2026: Over 550 new patient registrations and more than 300 admissions in the first quarter; MR-LINAC was commissioned in July.
• Peak EBITDA loss believed to be behind: Most costs were incurred in Q1; management expects losses to decline "quite reasonably in the next few quarters" as clinician practices ramp, insurance empanelment completes, and revenue scales.
• Breakeven and utilization timeline: Monthly breakeven expected this year; optimal utilization of 60–65% targeted in the third to fourth year of operation.
• Margin contribution ahead: As losses come down and the facility matures next year, North Bangalore becomes an incremental margin expansion lever for the consolidated business.

Mattoo: "I feel we have reached the peak EBITDA loss in this quarter. So from here on, we feel as we ramp up clinician practices, insurance empanelment happens and revenue goes up meaningfully, I think the losses will come down quite reasonably in the next few quarters."

Capacity Expansion & Capital Deployment

• Bed addition roadmap: 65 beds in FY27, 520 in FY28–FY29 (across 25 centers, with 6 hospitals receiving major additions), and 230 in FY30; nearly 60% of the FY28–FY29 additions are brownfield.
• Three greenfield projects: Whitefield (South cluster) likely operational by end-FY28, a Maharashtra project (West cluster) in the subsequent year; together they add 180 greenfield beds.
• Existing utilization headroom: The Southern cluster operated at 68% utilization in FY26 and can accommodate up to 75–80% before requiring new beds, providing near-term capacity to absorb volume growth.
• Vizag stake increased: Shareholding rose from 51% to 85%, funded by ₹150 crore from the rights issue proceeds.
• Annual bed planning process: Management conducts a Jan–Mar assessment each year to determine where beds are needed based on capacity and utilization trends.
• Growth funding: Future expansion to be funded through a mix of debt and internal accruals; interest costs are expected to moderate compared to last year.

Strategic & Clinical Investments

• Fertility business divested: The Milann exit was completed at end-June 2026, sharpening focus on core oncology.
• Technology and capability build: Two surgical robotic systems added (new at Nashik, replacement at Bangalore CoE); a new LINAC commissioned in Rajkot, completing its transition to a Comprehensive Cancer Center; TomoTherapy units and MR-LINAC added; CAR-T cell therapy programs being established across several centers alongside Bone Marrow Transplant programs.
• Clinician recruitment: Approximately 20 oncologists onboarded in the last four to five months, supporting the clinical complexity push.
• Case mix ambition: Investments in precision diagnostics, precision oncology, targeted cell therapies, robotic surgery, and multidisciplinary clinical protocols are intended to shift the case mix toward more complex, higher-margin work.

Mattoo: "Our objective is not to only grow faster, but to grow with a better quality of earnings by treating more complex oncology cases, improving our patient mix, enhancing productivity and generating stronger returns on the capital we deploy."

Guidance & Commitments

Key Metrics